Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

39P - The lung immune prognostic index (LIPI) as prognostic factor in solid tumours: The experience of a community hospital

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Marina Vitorino

Citation

Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391

Authors

M. Vitorino, T. Tomás, S. de Almeida, M. Honório, M. Silva

Author affiliations

  • Hospital Professor Doutor Fernando Fonseca EPE (Hospital Amadora/Sintra), Lisbon/PT
More

Abstract 39P

Background

Immune checkpoint inhibitors (ICI) have changed advanced cancer treatment over the last few years. Evidence suggests that tumor-associated inflammation influence the host immune response and its response to immunotherapy. Lung Immune Prognostic Index (LIPI) is a score that is correlated with patients' outcomes treated with ICI in certain malignancies.

Methods

Retrospective analysis of 114 patients with solid tumors who received ICI since January 2016 til June 2020. LIPI score was classified in 3 groups: good (G), intermediate (I) and poor (P) and was tested for association with overall survival (OS) and progression free survival (PFS).

Results

From 114 patients treated with ICI, 84 (73.7%) were male, with a mean age of 61 years. Fourteen (12.3%) were treatment-naive. Nivolumab was used in 59 patients (51.8%), pembrolizumab in 50 (43.9%), durvalumab in 4 (3.5%) and atezolizumab in 1 (0.9%). Regarding tumor sites: 80.7% NSCLC, 7.9% bladder, 5.3% renal, 2.6% colorectal, 0.9% breast, 0.9% thymus, 0.9% mesothelioma and 0.9% nasopharynx. According to LIPI classification, 11 patients (9.6%) were in P group, 37 (32.5%) in I group and 66 (57.9%) in G group. Median OS was 2.3m (95% CI 0.0 – 4.6) in P group, 12.2m (95% CI 2.4 – 22.0) in I group and 16.3m (95% CI 12.2 – 20.4) in G group (p<0.001). Median PFS was 1.8m (95% CI 0.5 – 3.2m) in P group, 7.1m (95% CI 2.4 – 11.8) in I group and 8.9m (95% CI 5.0 – 12.7) in G group (p<0.001). Cox regression analysis showed a better OS and PFS in G group comparing with I group (HR 7.1 (95% CI 3.2 – 15.9) and HR 5.0 (95% CI 2.4 – 10.5), respectively). No stastically significant difference for P group.

Conclusions

Poor LIPI score was associated with worse outcomes for ICI treated patients with solid tumors. LIPI score may be a useful tool to select patients for ICI treatment.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings